Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

Eisai announces positive results from a 12,000-subject cardiovascular (CV) outcomes study, CAMELLIA-TIMI 61, assessing the safety and potential CV benefits of weight loss med BELVIQ (lorcaserin HCl). The study was a post-marketing requirement by the FDA. https://www.biospace.com/article/releases/eisai-inc-announces-positive-topline-results-from-camellia-timi-61-a-large-scale-cardiovascular-outcome-trial-for-the-anti-obesity-agent-belviq-/